Results 'positive' for nasal spray 3rd phase trials: Glenmark

Glenmark Pharmaceuticals today said its investigational fixed-dose combination nasal spray, being studied for the treatment of seasonal allergic rhinitis, has shown positive results.

The results for GSP 301, a fixed-dose combination of mometasone furoate 25 mcg and olopatadine hydrochloride 665 mcg are from a recently completed phase III trial assessing its efficacy and safety versus mometasone, olopatadine or placebo, it said in a BSE filing.

The company's President and Chief Medical Officer Fred Grossman said: "We continue to advance our respiratory pipeline and are pleased to report positive results of GSP 301 in seasonal allergic rhinitis."

The US-based trial enrolled 1,176 adults and adolescents 12 years of age and older for 14-days of twice daily treatment with GSP 301.

The stock of the company was trading 0.24 per cent down at Rs 869.30 in the afternoon on BSE.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)